ReviewJournal of neurogastroenterology and motility2022
Bile Acid and Gut Microbiota in Irritable Bowel Syndrome.
Review in Journal of neurogastroenterology and motility, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- A bibliometric analysis of global research status and trends in irritable bowel syndrome and gut microbiota metabolites.Frontiers in microbiology · 2025Pooled it
- Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial.Nature communications · 2024Trial
- Cholecystectomy and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 3,511,681 Patients.Journal of clinical medicine · 2026Review
- Dual regulation of bile acids: ameliorating hepatic glycolipid disorders and restoring intestinal health in HFHC-challenged Yellow River carp (Cyprinus carpio L.).BMC veterinary research · 2026Article
- Is MASLD Not Just a Liver Disease? Bidirectional Gut-Liver Crosstalk as a Driver of Chronic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- Time-of-day difference in iron supplementation in iron-deficient pregnant model mice.NPJ science of food · 2026Article
- Probiotics in irritable bowel syndrome: strain-specific effects, diet, and biomarker timing.Frontiers in cellular and infection microbiology · 2026Article
- Review
- Unraveling the Association Between Fibromyalgia and Irritable Bowel Syndrome: A Systematic Review.Cureus · 2025Review
- Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights.International journal of molecular sciences · 2025Review
- Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Silibinin Alleviates Liver Oxidative Stress in D-Galactose-Treated Kunming Mice via Microbiota Homeostasis in a Microbiota-Dependent Manner.Antioxidants (Basel, Switzerland) · 2025Article
- Common misconceptions and controversies in the management of irritable bowel syndrome.Nature reviews. Gastroenterology & hepatology · 2025Review
- Metabolomic profiles in serum uncover novel biomarkers in children with Williams-Beuren syndrome.Scientific reports · 2025Article
- Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.Frontiers in immunology · 2025Review
- Alteration in gut microbiota after colonoscopy: proposed mechanisms and the role of probiotic interventions.Clinical endoscopy · 2025Review
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- FMT and TCM to treat diarrhoeal irritable bowel syndrome with induced spleen deficiency syndrome- microbiomic and metabolomic insights.BMC microbiology · 2024Article
- Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism.Cell proliferation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota and their metabolites like bile acid (BA) have been investigated as causes of irritable bowel syndrome (IBS) symptoms. Primary BAs are synthesized and conjugated in the liver and released into the duodenum. BA biotransformation by gut microbiota begins in the intestine and results in production of a broad range of secondary BAs. Deconjugation is considered the gateway reaction for further modification and is mediated by bile salt hydrolase, which is widely expressed by the gut microbiota. However, gut bacteria that convert primary BAs to secondary BAs belong to a limited number of species, mainly Clostridiales. Like gut microbiota modify BA profile, BAs can shape gut microbiota via direct and indirect actions. BAs have prosecretory effects and regulates gut motility. BAs can also affect gut sensitivity. Because of the vital role of the gut microbiota and BAs in gut function, their bidirectional relationship may contribute to the pathophysiology of IBS. Individuals with IBS have been reported to have altered microbial profiles and modified BA profiles. A significant increase in fecal primary BA and a corresponding decrease in secondary BA have been observed in IBS with predominant diarrhea. In addition, primary BA was positively correlated with IBS symptoms. In IBS with predominant diarrhea, bacteria with reduced abundance mainly belonged to the genera in Ruminococcaceae and exhibited a negative correlation with primary BAs. Integrating the analysis of the gut microbiota and BAs could better understanding of IBS pathophysiology. The gap in this field needs to be further filled in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.